In 2025, Sino Biopharmaceutical conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 12,610.23a | 13,372.78a | 11,227.25a | |
Total Waste Recovered | N/A | N/A | N/A | |
Total Hazardous Waste Generated | 9,936.51a | 10,341.35a | 7,624.66a | |
Non-Hazardous Waste Disposed | 2,673.72a | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, Sino Biopharmaceutical generated a total of 12,610 metric tonnes of waste.a
Of this amount, 78.8% of Sino Biopharmaceutical's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.21.2% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, Sino Biopharmaceutical's total waste generation rose by 12.32%, but dropped by 5.7% in 2025, indicating a possible turning point driven by improved waste-reduction practices or production slowdowns.a
Over the same period, the share of hazardous waste in Sino Biopharmaceutical's total output increased by 16.03%, including a further 1.9% rise in 2025, suggesting a troubling upward shift toward more environmentally harmful waste streams that could raise compliance costs and environmental risks.a
Overall, while Sino Biopharmaceutical has recently reduced waste output, its hazardous waste share continues to rise, raising concerns about treatment efficiency or growing reliance on harmful materials despite short-term volume improvements.a